EUVIMEDEUVIMED entdecken
Crossref

Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer

Jingjing Peng, Xiaoyu Ding, Celia Xiaojing Chen, Pei Zhao, Xiao Ding iD, Man Zhang, Alex Aliper iD, Feng Ren iD, Hongfu Lu iD, Alex Zhavoronkov iD

Journal of Medicinal Chemistry · 12.12.2024 · 67 (23) · 21520-21544

DOI: 10.1021/acs.jmedchem.4c02421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 25.11.2024. Verfasst von Jingjing Peng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Protein Kinase Inhibitors, Protein Serine-Threonine Kinases, Pyridines. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematopoietic progenitor kinase 1 (HPK1) has emerged as an attractive target for immunotherapy due to its critical role in T cell activation and proliferation. The major challenge in developing HPK1 inhibitors lies in balancing kinase selectivity, pharmacokinetic (PK) properties, and therapeutic efficacy. In this study, we report a series of pyridine-2-carboxamide analogues demonstrating strong HPK1 inhibitory activity in enzymatic and cellular assays, along with good kinase selectivity. Among these analogues, compound 19 showed good in vitro HPK1 inhibitory activity, excellent kinase selectivity (>637-fold vs GCK-like kinase and >1022-fold vs LCK), and robust in vivo efficacy in the CT26 (tumor growth inhibition (TGI) = 94.3%, 2/6 CRs) and MC38 murine colorectal cancer models (TGI = 83.3%, 1/6 complete response) when administered in combination with anti-PD-1. Compound 19 also demonstrated adequate in vitro ADME and in vivo PK properties, displaying good oral bioavailability across multiple species (F % = 35-63). These findings summarize our compound's favorable safety and efficacy profiles, justifying its testing in future translational studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsProtein Kinase InhibitorsProtein Serine-Threonine KinasesPyridinesAnimalsFemaleHumansMaleMiceCell Line, TumorCell ProliferationDrug DiscoveryStructure-Activity RelationshipBenzimidazoles

Substanzen

Antineoplastic Agentshematopoietic progenitor kinase 1Protein Kinase InhibitorsProtein Serine-Threonine KinasesPyridinesBenzimidazoles

Autor:innen und Institutionen

  • Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.
  • Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE.

ORCID-Profile: Xiao Ding, Alex Aliper, Feng Ren, Hongfu Lu, Alex Zhavoronkov

Zitieren

APA

Peng, J., Ding, X., Chen, C. X., Zhao, P., Ding, X., Zhang, M., Aliper, A., Ren, F., Lu, H., & Zhavoronkov, A. (2024). Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry, 67(23), 21520-21544. https://doi.org/10.1021/acs.jmedchem.4c02421

Vancouver

Peng J, Ding X, Chen CX, Zhao P, Ding X, Zhang M, et al. Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry. 2024;67(23):21520-21544. doi:10.1021/acs.jmedchem.4c02421

BibTeX
@article{Peng2024,
  author = {Peng, Jingjing and Ding, Xiaoyu and Chen, Celia Xiaojing and Zhao, Pei and Ding, Xiao and Zhang, Man and Aliper, Alex and Ren, Feng and Lu, Hongfu and Zhavoronkov, Alex},
  title = {Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {23},
  pages = {21520--21544},
  doi = {10.1021/acs.jmedchem.4c02421}
}
Kostenlos starten →